- Meeting abstract
- Open Access
Antibiotics and multi-resistant organisms
© Tzialla et al. 2015
- Published: 24 September 2015
- Antibiotic Resistance
- Neonatal Intensive Care Unit
The development of antibiotic resistance is a normal evolutionary process for microorganisms, but it is accelerated by the selective pressure exerted by the widespread use of antibacterial drugs.
Nearly all very low birth weight infants admitted to neonatal intensive care units (NICUs) receive an empirical antibiotic treatment in the first days of life, despite the evidence of sterile cultures [1, 2].
Several studies show that widespread and inappropriate use of antibiotics is very common in NICUs and that the overuse of antibiotics like third-generation cephalosporins favors the emergence of multi-resistant (MR)bacteria in NICUs [1, 2]. A recent study describes1,106 episodesof bacteremiain a NICU: 35.5% were caused bygram-negative bacteria (GNB), and18.6%byMR strains. In the multivariate analysisthe authors identifiesasindependent risk factorforthe emergence of resistance the exposure to third-generation cephalosporins, and carbapenems.
Glycopeptide antibiotics remain adequate as treatment of most staphylococcal infections and vancomycin is the drug of choice for serious infections [1, 4]. However in case of infections due to Gram-positive bacteria (GPB) unresponsive to vancomycin, linezolid has been the most used in neonatal settings. Several novel antibiotics active against GPB are currently in diverse phases of development [1, 4].
GNB are often resistant to at least one class of antibiotics that is used as standard, and may be from time to time resistant to all-first-line antibiotics. The development of new antibiotics active against resistant GNB has not progressed in parallel with increasing rates of resistance. This scenario of limited therapeutic options has prompted renewed interest in older and more toxic antimicrobials [4, 5].
Since antibiotic resistance cannot be eradicated, different strategies have been proposed to slow the development and spread of MR that aim to [6, 7]: 1)improve the knowledge of MR bacteria and antibiotic use through surveillance at national and international levels,2) conserve the effectiveness of existing treatments and3) stimulate the development of new antibiotics, alternativetreatmentsand preventive strategies
Antibiotic resistance is a public health concern worldwide. Although some important molecules are currently in diverse phases of development for treatment of infections due to resistant GPB, very few drugs have been reached advanced stages of development for infection due to MR gram-negative bacilli. At this point it is essential to preserve the efficacy of existing drugs while efforts to develop new treatment options proceed.
- Patel SJ, Saiman L: Antibiotic Resistance in Neonatal Intensive Care Unit Pathogens: Mechanism, Clinical Impact, and Prevention including Antibiotic Stewardship. ClinPerinatol. 2010, 37: 547-563.Google Scholar
- Russell AB, Sharland M, Heath PT: Improving antibiotic prescribing in neonatal units: time to act. Arch Dis Fetal Neonatal. 2012, 97: F 141-146. 10.1136/adc.2007.120709.View ArticleGoogle Scholar
- Tsai M-H, Chu S-M, Hsu J-F, Lien R, Huang H-R, Chiang M-C, et al: Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. Pediatrics. 2014, 133: e 322-329. 10.1542/peds.2013-1248.View ArticleGoogle Scholar
- Gray JW, Patel M: Management of antibiotic-resistant infection in the newborn. Arch Dis Child EducPract. 2011, 96: 122-127. 10.1136/adc.2011.300163.85.View ArticleGoogle Scholar
- Gray JW, Ubhi H, Milner P: Antimicrobial treatment of serious gram-negative infections in newborns. Curr Infect Dis Rep. 2014, 16: 400-408.View ArticlePubMedGoogle Scholar
- World Health Organization: Antimicrobial resistance: Global report on surveillance. 2014Google Scholar
- Spellberg B, Gilbert DN: The future of antibiotics and resistance: a tribute to a career of leadership by. John Bartlett CID. 2014, 59: S71-S75.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.